SCHEMBL3853370

SCHEMBL3853370

CCOC(=O)CC(=O)NN=C(C(=O)OCC)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
TSHR P16473 1/20 0.42
TP53 P04637 2/20 0.41
POLB P06746 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPK1 P28482 2/20 0.40
GAA P10253 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853365 1.00 SMN1; SMN2 (0.55) SMN1; SMN2MAPTLMNATSHRTP53
SCHEMBL3846820 0.85 SMN1; SMN2 (0.58) SMN1; SMN2MAPTLMNATSHRNPC1
SCHEMBL3853477 0.85 SMN1; SMN2 (0.54) SMN1; SMN2MAPTLMNATSHRPOLB
SCHEMBL3846821 0.85 SMN1; SMN2 (0.58) SMN1; SMN2MAPTLMNATSHRNPC1
SCHEMBL3853475 0.85 SMN1; SMN2 (0.54) SMN1; SMN2MAPTLMNATSHRPOLB
SCHEMBL3849713 0.84 SMN1; SMN2 (0.72) SMN1; SMN2MAPTLMNATSHRNPC1
SCHEMBL3849710 0.84 SMN1; SMN2 (0.72) SMN1; SMN2MAPTLMNATSHRNPC1
SCHEMBL3846060 0.84 SMN1; SMN2 (0.53) SMN1; SMN2MAPTLMNATSHRPOLB
SCHEMBL3846064 0.84 SMN1; SMN2 (0.53) SMN1; SMN2MAPTLMNATSHRPOLB
SCHEMBL3854746 0.77 SMN1; SMN2 (0.48) SMN1; SMN2MAPTLMNATSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN SMN1; SMN2 3490/4885MAPT 4802/4885LMNA 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.